Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review. (PubMed, J Clin Lipidol) - Oct 7, 2026 - "Emerging Lp(a)-targeted therapies achieve significant reductions in circulating Lp(a) concentrations and represent a promising strategy for addressing residual cardiovascular risk associated with elevated Lp(a). Ongoing large-scale cardiovascular outcome trials will determine whether pharmacologic lowering of Lp(a) translates into reductions in cardiovascular events."
Journal • Review • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Myocardial Infarction
|
|
Anurag Mehta; Dave L Dixon; Fadi N Salloum; Kayla Harley; Mathew Ambrosio; Matthew K Campbell; Nicholas Ws Chew; Pamela L Alebna; Yip Han Chin
|